La vendita allo scoperto per CHS dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CHS. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CHS (NASDAQ:CHSCN) Azioni, Report sulle vendite allo scoperto

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

Cum Red Pfd Registered Shs -B- Series -2-

JMP Securities analyst Patrick Walravens reiterates C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a Market Outperform and maintains $50 price target.

News

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on C3.ai, Maintains $50 Price Target

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Southern Missouri Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMBC#NASDAQ">SMBC</a>) with a Market Perform and raises the price target from $60 to $63.

SMBC

Keefe, Bruyette & Woods Maintains Market Perform on Southern Missouri Bancorp, Raises Price Target to $63

Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) reported better-than-expected second-quarter financial<a href="https://www.benzinga.com/quote/BX/earnings"> results on Thursday</a>.
The strong performance was fueled by a 25% increase in distributable earnings and robust growth across its key business segments, pushing the firm's total assets under management to a new industry record of over $1.2 trillion.
Blackstone reported second-quarter fiscal year segment revenues of $3.075 billion, up 22% Y/Y, beating the analyst consensus estimate of $2.778 billion. Distributable earnings (DE) rose 25% Y/Y to $1.57 billion.
Chairman and CEO Stephen A. Schwarzman said Blackstone achieved strong second-quarter results, driven by broad growth across private wealth, credit and insurance, and infrastructure. He noted that the firm significantly increased earnings and pushed total assets under management to over $1.2 trillion, marking a new industry record. He emphasized that, above all, Blackstone continued to deliver strong investment performance for its limited partners, with the highest level of fund appreciation in nearly four years.
Blackstone shares gained 3.6% to close at $178.11 on Thursday.
These analysts made changes to their price targets on Blackstone following earnings announcement.
<ul class="wp-block-list">
<li>Deutsche Bank analyst Brian Brungardt maintained Blackstone with a Buy and raised the price target from $170 to $192.</li>
<li>Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained the stock with a Market Perform and raised the price target from $168 to $180.</li>
</ul>
Considering buying BX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092820/image-403-1024x560.png" alt="" class="wp-image-1000814" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092820/image-403-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092820/image-403-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092820/image-403-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092820/image-403.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

These Analysts Raise Their Forecasts On Blackstone Following Q2 Earnings

Publicly traded companies are increasingly integrating cryptocurrencies other than Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), into their treasuries, with significant investments announced in Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Binance Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) and <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46567973/ethereum-treasury-company-trend-will-accelerate-says-bitwises-matt-hougan-heres-what-it-means-for-eths-price">other tokens this year</a>.
What Happened: This trend, driven by firms across biotech, fintech, and Web3 sectors, reflects a strategic pivot to diversify financial assets and capitalize on the growing legitimacy of digital currencies.
SharpLink Gaming, a Minnesota-based affiliate marketing firm listed on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>), has emerged as a leader in altcoin treasury adoption, focusing on Ethereum. 
As of July 22, SharpLink holds 205,000 ETH, valued at approximately $1.35 billion, making it the second-largest corporate holder of Ethereum <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46515365/ethereum-roars-to-3800-whats-driving-the-surge">behind the Ethereum Foundation.</a>
The company, now chaired by Joe Lubin, co-founder of Ethereum and CEO of Consensys, announced plans in May 2025 to raise $425 million to build its ETH treasury. 
Since June 2, SharpLink has committed all its ETH to staking and restaking protocols, generating a yield of 322 ETH. 
The firm's stock surged from under $4 to nearly $40 following the announcement, though it stabilized at $16.29 by mid-July, reflecting sustained investor interest.
Solana has also gained traction as a treasury asset. 
DeFi Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>), formerly Janover, a real estate software firm, rebranded in April 2025 after Kraken executives took leadership roles. 
The company raised $24 million in a private equity deal to acquire SOL, holding 395,000 tokens by May 31.
Separately, Upexi, a consumer product company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>), secured $100 million in funding led by venture firm GSR, amassing 735,692 SOL by June 24.
These holdings, valued at over $100 million and $331 million respectively, underscore Solana's appeal due to its high-throughput DeFi ecosystem and low transaction costs.
XRP, the native token of the Ripple network, is another altcoin attracting corporate investment. 
Trident Financial Solutions, a Singapore-based fintech company, announced plans to raise $7.5 million to build a $500 million XRP treasury, citing its efficiency in cross-border payments. 
Similarly, Webus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>), a Chinese travel booking firm, disclosed intentions to acquire $500 million in XRP, with a $300 million capital raise already completed. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46627175/4000-is-ethereums-last-hurdle-before-price-discovery-says-galaxy-digitals-mike-novogratz">$4,000 Is Ethereum&#8217;s Last Hurdle Before Price Discovery, Says Galaxy Digital&#8217;s Mike Novogratz</a>
These initiatives align with XRP's growing adoption by financial institutions, as evidenced by its use in Unicredit's payment solutions for transfers from Portugal to Brazil, announced in early 2025.
Windtree Therapeutics, a biotechnology firm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>), has committed to Binance Coin as its treasury asset.
On July 24, the company <a href="https://www.globenewswire.com/news-release/2025/07/24/3121106/0/en/Windtree-Therapeutics-Announces-Up-To-520-Million-in-New-Funding-to-Amplify-BNB-Cryptocurrency-Treasury-Strategy.html">announced </a>a $500 million equity line of credit (ELOC) and a $20 million stock purchase agreement with Build and Build Corp., allocating 99% of the $520 million proceeds to purchase BNB.
Windtree's total commitment could reach $700 million, pending stockholder approval to increase authorized shares. 
The company has partnered with Kraken to manage custody and trading of its BNB holdings, leveraging the token's robust performance, which saw a 17.5% value increase in July 2025, reaching $759 per token.
Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>), a Web3 infrastructure provider, also announced a BNB-focused treasury strategy, unveiling a $1 billion initiative in June.
By July, the company had acquired 120,000 BNB tokens, valued at approximately $90 million, with an initial $50 million purchase followed by a $34.8 million investment.
Nano Labs' strategy aims to capitalize on BNB's role in the Binance Smart Chain's DeFi ecosystem.
Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>), a U.S.-based fintech firm, launched a $500 million "DeFi Basket Treasury" on July 14, 2025, diversifying across multiple altcoins: Ethereum, Solana, XRP, BNB, and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>). 
The company plans to acquire these assets using existing cash reserves and future fundraising, focusing on yield-generating DeFi protocols and Solana integration. 
This diversified approach reflects a broader trend of firms seeking exposure to multiple altcoins to mitigate risk and enhance returns.
Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>), a U.S.-based fitness equipment manufacturer, announced on June 11, plans to raise $500 million to establish a treasury of Fetch.ai tokens, linked to the Fetch.ai large language model.
This move highlights the growing interest in AI-related altcoins, though specific holdings were not disclosed by July 2025.
Animoca Brands' "Altcoin Strategic Reserves" report, published July 18, 2025, notes that public companies hold over $1.4 billion in altcoins, with Ethereum dominating but Solana, XRP, and BNB gaining ground. 
The report highlights a 150% average stock price increase within 24 hours of altcoin treasury announcements, with gains reaching 226% after 30 days. 
What&#8217;s Next: This market response underscores investor enthusiasm for altcoin exposure through public equities, particularly as altcoin ETFs remain limited.
The adoption of altcoin treasuries is enabled by recent U.S. Financial Accounting Standards Board (FASB) rule changes, allowing fair value accounting for crypto assets, which simplifies balance sheet management. 
However, risks persist, including altcoin volatility, regulatory uncertainties, and potential shareholder dilution from fundraising efforts. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46611509/remember-cryptopunks-this-public-company-just-traded-5-15-million-worth-of-stock-for-a-jpeg">Remember CryptoPunks? This Public Company Just Traded $5.15 Million Worth Of Stock For A JPEG</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BNB

$BTC

$ETH

$SOL

$XRP

DFDV

SBET

TRNR

UPXI

WETO

WINT

Why Are Public Companies Ammassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin?

Keefe, Bruyette &amp; Woods analyst Damon Delmonte reiterates QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) with a Outperform and raises the price target from $90 to $92.

QCRH

Keefe, Bruyette & Woods Reiterates Outperform on QCR Hldgs, Raises Price Target to $92

Keefe, Bruyette &amp; Woods analyst Bose George downgrades PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) from Outperform to Market Perform and lowers the price target from $14.5 to $13.5.

Downgrades

Keefe, Bruyette & Woods Downgrades PennyMac Mortgage IT to Market Perform, Lowers Price Target to $13.5

The European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) donanemab for early symptomatic Alzheimer&#8217;s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">heterozygotes or non-carriers</a>.
For more about the current price of LLY stock, <a href="https://www.benzinga.com/quote/LLY">click here.</a>
Donanemab, a monthly infusion, is currently marketed as Kisunla in&nbsp;the <a href="https://www.benzinga.com/pressreleases/25/07/n46625992/donanemab-receives-positive-opinion-from-the-committee-for-medicinal-products-for-human-use-chmp-i" target="_blank" rel="noreferrer noopener">U.S.&nbsp;and other countries</a>.
In&nbsp;the U.S.,&nbsp;Japan,&nbsp;China and many other countries, donanemab is approved for patients regardless of ApoE4 status.
Donanemab is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.
The European Commission is expected to make a regulatory decision on donanemab in the coming months.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/46173089/alzheimers-setback-hits-inmune-bio-stock-but-fda-hopes-remain" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s Setback Hits INmune Bio Stock, But FDA Hopes Remain</a>
Alzheimer&#8217;s disease currently affects as many as 6.9 million people in Europe,&nbsp;with this figure expected to almost double by 2050 as aging populations continue to increase.
Approximately one-third of individuals with mild cognitive impairment or mild dementia due to Alzheimer&#8217;s disease progress to the next clinical stage of disease in one year.
The positive opinion was primarily based on clinical trial data from the TRAILBLAZER-ALZ 2 clinical trial, which demonstrated that donanemab significantly slowed cognitive and functional decline and reduced the risk of progressing to the next clinical stage of disease, and the TRAILBLAZER-ALZ 6 clinical trial, which evaluated a modified titration dosing schedule.
In the TRAILBLAZER-ALZ 6 study, the modified titration schedule significantly lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) versus the dosing schedule used in TRAILBLAZER-ALZ 2 at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal and P-tau217 reduction
In July, the U.S. Food and Drug Administration <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46319441/fda-approves-new-dosing-schedule-for-eli-lillys-kisunla-in-alzheimers-treatment" rel="noreferrer noopener">approved a label update</a> with a new recommended titration dosing schedule for&nbsp;Kisunla.
The FDA approved the&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620867/eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-a" rel="noreferrer noopener">drug in July 2024</a>.
In the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41608511/eli-lilly-says-new-data-can-potentially-provide-path-to-improved-donanemab-profile-by-lower-risk-" rel="noreferrer noopener">TRAILBLAZER-ALZ 6 study</a>, the modified titration schedule significantly reduced the incidence of ARIA-E compared to the original dosing schedule at 24 and 52 weeks, while achieving similar levels of amyloid plaque removal&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46314838/fda-approves-updated-label-for-lillys-kisunla-donanemab-azbt-with-new-dosing-in-early-symptomatic-" rel="noreferrer noopener">and P-tau217 reduction</a>.
In other news, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) agreed to acquire Vigil Neuroscience Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) for&nbsp;an <a href="https://www.benzinga.com/general/biotech/25/05/45561443/sanofi-boosts-alzheimers-pipeline-with-vigil-neuroscience-acquisition" target="_blank" rel="noreferrer noopener">approximately $470 million equity value</a>. The acquisition strengthens Sanofi's neurology pipeline with VG-3927, an oral TREM2 agonist for Alzheimer's disease.
LLY Price Action: Eli Lilly stock is up 0.42% at $805.77&nbsp;during the premarket session at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46626902/chevron-set-to-restart-venezuela-oil-operations-after-trump-reversal" target="_blank" rel="noreferrer noopener">Chevron Set To Restart Venezuela Oil Operations After Trump Reversal</a></li>
</ul>
Photo: Shutterstock

Biotech

Eurozone

Health Care

General

VIGL

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

Charter Communications (NASDAQ: CHTR) stock declined after it released its <a href="https://www.benzinga.com/pressreleases/25/07/n46626616/charter-announces-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">fiscal second-quarter</a> 2025 results on Friday. 
The company reported quarterly revenue growth of 0.6% year-on-year to $13.77 billion, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of $13.76 billion.
Earnings per share of $9.18 missed the analyst consensus estimate of $9.80.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45502573/charters-proposed-cox-deal-could-challenge-comcast-surpass-att-in-broadband" target="_blank" rel="noreferrer noopener">Charter&#8217;s Proposed Cox Deal Could Challenge Comcast, Surpass AT&amp;T In Broadband</a>
The topline performance reflects revenue growth of 24.9% for residential mobile service, 2.8% for residential Internet, and 18.9% for other revenue.
Charter lost 117,000 internet customers, compared to a decline of 149,000 during the second-quarter of 2024 which included the impact of approximately 50,000 disconnects related to the end of the FCC&#8217;s Affordable Connectivity Program subsidies.
Charter&#8217;s residential video customers decreased by 80,000 compared to 408,000 in the previous year.
Charter&#8217;s mobile lines increased by 500,000 during the quarter, reaching 10.9 million as of June 30. AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) added 401,000 <a href="https://www.benzinga.com/markets/earnings/25/07/46570015/atts-discount-bundles-fuel-subscriber-gains-tax-savings-to-supercharge-fiber-expansion" target="_blank" rel="noreferrer noopener">postpaid phone customers</a> in the second quarter, down slightly from 419,000 last year but still strong. In contrast, Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) lost 9,000 postpaid phone connections, missing analyst expectations for a 13,000 gain.
Charter&#8217;s adjusted EBITDA margin remained flat at 41.4%.
The quarterly free cash flow of $1.1 billion decreased from $1.3 billion in the prior year, primarily driven by lower net cash flows from operating activities.
As of June 30, Charter served 29.9 million residential and small business Internet customers.
Net cash flow from operating activities totaled $3.6 billion during the quarter. As of June 30, the company held $606 million in cash and equivalents.
During the quarter, Charter purchased 4.5 million Charter and Charter Communications shares totaling&nbsp;$1.7 billion.
2025 Outlook: Charter Communications&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">expects a capex</a>&nbsp;of approximately&nbsp;$11.5 billion (<a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/45007666/charter-loses-internet-and-tv-subscribers-but-beats-rivals-with-strong-mobile-line-gains" rel="noreferrer noopener">prior $12 billion</a>) versus $11.27 billion&nbsp;in fiscal 2024. The decrease primarily reflects the timing of network evolution spending and lower commercial and subsidized rural line extensions spending.
Charter stock gained 11% year-to-date compared to the NASDAQ Composite Index&#8217;s (which includes the stock) over 9% returns.
Price Action: Charter Communications stock is down 10.6% to $339.61 in the premarket at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/45119505/t-mobiles-consistent-subscriber-growth-and-strong-market-trends-prompt-analyst-upgrade" target="_blank" rel="noreferrer noopener">T-Mobile Stock Gets A Lift As Subscriber Growth Holds Steady</a></li>
</ul>
Image: Shutterstock

Guidance

CHTR

Charter Stock Slides Despite Revenue Beat—Mobile Gains Offset By Internet, Video Subscriber Losses

Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) posted better-than-expected second-quarter results after <a href="https://www.benzinga.com/quote/COUR">Thursday&#8217;s closing bell</a>.
Coursera reported quarterly earnings of 12 cents per share, which beat the analyst consensus estimate of nine cents. Quarterly revenue clocked in at $187.1 million, which beat the Street estimate of $180.48 million.
"Coursera's market opportunity continues to expand with the global demand to embrace new technology and skills. This quarter, we attracted more than seven million new learners looking to master emerging skills that can advance their careers," said Coursera CEO Greg Hart.
Coursera raised its full year 2025 revenue outlook by $17 million to a range of $738 to $746 million.
Coursera shares gained 1.3% to close at $9.08 on Thursday.
These analysts made changes to their price targets on Coursera following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Ryan MacDonald maintained Coursera with a Buy and raised the price target from $11 to $14.</li>
<li>B of A Securities analyst Nafeesa Gupta upgraded Coursera from Underperform to Neutral and raised the price target from $7 to $12.</li>
<li>Telsey Advisory Group analyst Sarang Vora maintained the stock with an Outperform rating and raised the price target from $12 to $14.</li>
<li>Keybanc analyst Bradley Thomas maintained Coursera with an Overweight rating and boosted the price target from $11 to $12.</li>
<li>Morgan Stanley analyst Josh Baer maintained the stock with an Equal-Weight rating and raised the price target from $11 to $12.</li>
<li>Cantor Fitzgerald analyst Yi Fu Lee maintained the stock with an Overweight rating and lifted the price target from $10 to $13.</li>
</ul>
Considering buying COUR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/COUR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092239/image-402-1024x582.png" alt="" class="wp-image-1000792" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092239/image-402-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092239/image-402-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092239/image-402-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25092239/image-402.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo via Shutterstock

COUR

Coursera Analysts Boost Their Forecasts After Upbeat Q2 Results

Keefe, Bruyette &amp; Woods analyst Bose George maintains Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) with a Outperform and raises the price target from $20.5 to $21.5.

Keefe, Bruyette & Woods Maintains Outperform on Annaly Capital Management, Raises Price Target to $21.5

Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) (the "Company," "Volcon" or "Empery Digital") today announced that as of July 25th at 8:00am ET, the Company holds 3,183.37 BTC acquired for an aggregate purchase price of ~$375 million, reflecting an average purchase price of $117,697 per BTC. The Company has also sold various short-term put contracts giving the Company the opportunity to potentially buy additional BTC at $115,000, $116,000 and $117,000 while collecting option premium to reduce the cost of BTC. This aligns well with the Company's continued BTC acquisition strategy.
Additionally, the Company announced that its board of directors has authorized an increase in the current stock repurchase program. Volcon is now authorized to repurchase up to $100 million of the Company's outstanding shares of common stock, par value $0.00001, over the next 24 months. This repurchase program enables the Company the flexibility to support the NAV per share and potentially add BTC per share at share prices below NAV.
 &nbsp;

Buybacks

VLCN

Volcon Board Authorizes Stock Repurchase Of Up To $100M

Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) from Overweight to Equal-Weight and lowers the price target from $40 to $14.5.

NVCR

Wells Fargo Downgrades NovoCure to Equal-Weight, Lowers Price Target to $14.5

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $103 to $104.

NDAQ

Keefe, Bruyette & Woods Maintains Outperform on Nasdaq, Raises Price Target to $104

Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) (the "Company," "Volcon" or "Empery Digital") today announced that as of July 25th at 8:00am ET, the Company holds 3,183.37 BTC acquired for an aggregate purchase price of ~$375 million, reflecting an average purchase price of $117,697 per BTC. The Company has also sold various short-term put contracts giving the Company the opportunity to potentially buy additional BTC at $115,000, $116,000 and $117,000 while collecting option premium to reduce the cost of BTC. This aligns well with the Company's continued BTC acquisition strategy.

Volcon Discloses $375M Bitcoin Holdings, Acquires 3,183.37 BTC At $117K Average Purchase Price

Cantor Fitzgerald analyst Sarah James downgrades Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) from Overweight to Neutral and lowers the price target from $312 to $210.

Cantor Fitzgerald Downgrades Molina Healthcare to Neutral, Lowers Price Target to $210

Keefe, Bruyette &amp; Woods analyst Timothy Switzer reiterates Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) with a Market Perform and raises the price target from $36 to $37.

Keefe, Bruyette & Woods Reiterates Market Perform on Live Oak Bancshares, Raises Price Target to $37

Keefe, Bruyette &amp; Woods analyst Alex Bond maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Market Perform and raises the price target from $57 to $60.

Keefe, Bruyette & Woods Maintains Market Perform on Lazard, Raises Price Target to $60

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Ladder Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LADR#NYSE">LADR</a>) with a Outperform and raises the price target from $11.75 to $12.

LADR

Keefe, Bruyette & Woods Maintains Outperform on Ladder Capital, Raises Price Target to $12

<ul>
<li>INTC</li>
<li>UNH</li>
<li>TSLA</li>
<li>NVDA</li>
<li>$BTC</li>
<li>GLD</li>
<li>BULL</li>
<li>GOOGL</li>
<li>RKT</li>
<li>CORN</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BULL

CORN

GOOGL

INTC

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 25, 2025 (Via Swaggy Stocks)

WIIM

TROO

TROO stock has given up its prior gain. Troops shares were trading higher after the company initiated a stock repurchase agreement with an existing shareholder.

Archer-Daniels-Midland Company Common Stock

Archer-Daniels-Midland

AgriFORCE Growing Systems Ltd. - Common Shares

AgriFORCE Growing Systems

Alico

Bunge Global

CHS Inc - Class B Cumulative Redeemable Preferred Stock, Series 4

7.50% PRF PERPETUAL USD 25 - Class B Ser 4

CHS Inc - Class B Reset Rate Cumulative Redeemable Preferred Stock, Series 3

CHS Inc - Preferred Class B Series 2 Reset Rate

CHS Inc - Class B Cumulative Redeemable Preferred Stock

CHS Inc - 8% Cumulative Redeemable Preferred Stock

Cresud S.A.C.I.F. y A. - American Depositary Shares, each representing ten shares of Common Stock

Comments

CHS

Vendite allo scoperto

CHS (NASDAQ:CHSCN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO